WO2015068168A1 - Système et procédé pour traiter des troubles de l'œil et du cerveau - Google Patents
Système et procédé pour traiter des troubles de l'œil et du cerveau Download PDFInfo
- Publication number
- WO2015068168A1 WO2015068168A1 PCT/IL2014/050974 IL2014050974W WO2015068168A1 WO 2015068168 A1 WO2015068168 A1 WO 2015068168A1 IL 2014050974 W IL2014050974 W IL 2014050974W WO 2015068168 A1 WO2015068168 A1 WO 2015068168A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- display
- eye
- image
- visual
- brain
- Prior art date
Links
- 208000014644 Brain disease Diseases 0.000 title claims abstract description 6
- 238000000034 method Methods 0.000 title claims description 13
- 208000030533 eye disease Diseases 0.000 title description 3
- 230000000007 visual effect Effects 0.000 claims abstract description 91
- 210000004556 brain Anatomy 0.000 claims abstract description 52
- 208000004350 Strabismus Diseases 0.000 claims abstract description 19
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 16
- 201000009487 Amblyopia Diseases 0.000 claims abstract description 14
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 7
- 230000017531 blood circulation Effects 0.000 claims abstract description 7
- 230000008081 blood perfusion Effects 0.000 claims abstract description 6
- 208000032382 Ischaemic stroke Diseases 0.000 claims abstract description 5
- 210000001508 eye Anatomy 0.000 claims description 101
- 230000000638 stimulation Effects 0.000 claims description 18
- 238000012549 training Methods 0.000 claims description 11
- 210000003128 head Anatomy 0.000 claims description 10
- 206010047571 Visual impairment Diseases 0.000 claims description 5
- 230000013016 learning Effects 0.000 claims description 5
- 210000003205 muscle Anatomy 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 4
- 230000036961 partial effect Effects 0.000 claims description 4
- 230000003252 repetitive effect Effects 0.000 claims description 3
- 230000002747 voluntary effect Effects 0.000 claims description 3
- 230000003044 adaptive effect Effects 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 20
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 19
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 230000000926 neurological effect Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 8
- 230000004438 eyesight Effects 0.000 description 7
- 208000006011 Stroke Diseases 0.000 description 6
- 210000001328 optic nerve Anatomy 0.000 description 6
- 210000000857 visual cortex Anatomy 0.000 description 6
- 201000004569 Blindness Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000000763 evoking effect Effects 0.000 description 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000003190 augmentative effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000009251 neurologic dysfunction Effects 0.000 description 3
- 208000015015 neurological dysfunction Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000002645 vision therapy Methods 0.000 description 3
- 230000004304 visual acuity Effects 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- 210000000239 visual pathway Anatomy 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000003984 auditory pathway Anatomy 0.000 description 2
- 150000003943 catecholamines Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000004456 color vision Effects 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000004424 eye movement Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 208000001692 Esotropia Diseases 0.000 description 1
- 201000005538 Exotropia Diseases 0.000 description 1
- 206010015829 Extraocular muscle paresis Diseases 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000009893 Nonpenetrating Wounds Diseases 0.000 description 1
- 208000014723 Oculomotor Nerve disease Diseases 0.000 description 1
- 102100026450 POU domain, class 3, transcription factor 4 Human genes 0.000 description 1
- 101710133389 POU domain, class 3, transcription factor 4 Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000019194 Sorbus aucuparia Species 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000582857 Yanga Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 206010002537 anisometropia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000010442 axonal sprouting Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000000974 brodmann area Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000005682 chronic closed-angle glaucoma Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000036648 cognitive speed Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 201000006316 hypertropia Diseases 0.000 description 1
- 201000006309 hypotropia Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 230000004315 low visual acuity Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 201000005743 paralytic squint Diseases 0.000 description 1
- 208000028254 paralytic strabismus Diseases 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000006414 serbal de cazadores Nutrition 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000003956 synaptic plasticity Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000010981 turquoise Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 230000004400 visual pathway Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H5/00—Exercisers for the eyes
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
- G02B27/01—Head-up displays
- G02B27/017—Head mounted
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C7/00—Optical parts
- G02C7/02—Lenses; Lens systems ; Methods of designing lenses
- G02C7/08—Auxiliary lenses; Arrangements for varying focal length
- G02C7/086—Auxiliary lenses located directly on a main spectacle lens or in the immediate vicinity of main spectacles
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F1/00—Details not covered by groups G06F3/00 - G06F13/00 and G06F21/00
- G06F1/16—Constructional details or arrangements
- G06F1/1613—Constructional details or arrangements for portable computers
- G06F1/163—Wearable computers, e.g. on a belt
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5007—Control means thereof computer controlled
- A61H2201/501—Control means thereof computer controlled connected to external computer devices or networks
- A61H2201/5015—Control means thereof computer controlled connected to external computer devices or networks using specific interfaces or standards, e.g. USB, serial, parallel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5023—Interfaces to the user
- A61H2201/5038—Interfaces to the user freely programmable by the user
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/50—Control means thereof
- A61H2201/5023—Interfaces to the user
- A61H2201/5043—Displays
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
- G02B27/01—Head-up displays
- G02B27/0101—Head-up displays characterised by optical features
- G02B2027/0141—Head-up displays characterised by optical features characterised by the informative content of the display
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B27/00—Optical systems or apparatus not provided for by any of the groups G02B1/00 - G02B26/00, G02B30/00
- G02B27/01—Head-up displays
- G02B27/017—Head mounted
- G02B2027/0178—Eyeglass type
-
- G—PHYSICS
- G02—OPTICS
- G02C—SPECTACLES; SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURES AS SPECTACLES; CONTACT LENSES
- G02C2202/00—Generic optical aspects applicable to one or more of the subgroups of G02C7/00
- G02C2202/10—Optical elements and systems for visual disorders other than refractive errors, low vision
Definitions
- the present invention generally relates to systems and methods for treating eye and brain disorders, specifically, the present invention relates to visual and audible regimes designed to stimulate brain related pathways.
- the invention may apply to several medical conditions, general relevant background is provided for some of them.
- Amblyopia is characterized by poor or indistinct vision in an eye. It is one of the most common disorders of the visual system in childhood, affects 1-5% of the population, and is generally associated with a history of strabismus, anisometropia, or form- deprivation in early life [1]. Amblyopia is a developmental problem in the brain, not an organic problem in the eye. The part of the brain corresponding to the visual system from the affected eye is not stimulated properly, and develops abnormally.
- fMRI Blood oxygenation level-dependent functional magnetic resonance imaging
- One action of endogenous neurologicalmodulator release such as norepinephrine, acetylcholine, serotonin, or dopamine may be to adjust a favorable E/I balance (Bear and Singer, 1986; Kasamatsu, 1991; Kilgard and Merzenich, 1998; Bao et al., 2001; Weinberger, 2007; Maya Vetencourt et al., 2008; Goard and Dan, 2009).
- chronic treatment with the serotonin reuptake inhibitor (SSRI) fluoxetine restores visual function in amblyopic adult rats apparently by resetting E/I balance (Maya Vetencourt et al., 2008).
- This neurologicalchemical milieu can act in a cell-specific manner during periods of heightened arousal or focal attention (McCormick, 1989; Gil et al., 1997; Kawaguchi, 1997; Kawaguchi and Shindou, 1998; Xiang et al., 1998; Hsieh et al., 2000; Froemke et al., 2007).
- Action video game play may improve the efficiency of probabilistic inference in neural circuits, which in turn would provide a mechanistic explanation for the broad transfer such training engenders (Green et al., 2010b).
- These plastic changes have been shown to be long-lasting, with beneficial effects noted 6 months to 2 years after the end of intervention (Feng et al., 2007; Li et al., 2009b).
- Strabismus According to the American Association for Pediatric Ophthalmology and Strabismus (AAPOS), Strabismus is defined as any misalignment of the eyes, and is estimated to affect 4% of the U.S. population has strabismus. Strabismus is most commonly described by the direction of the eye misalignment; common types of strabismus are esotropia, exotropia, hypotropia, and hypertropia. Strabismus can also be described by its cause. The 3 cranial nerves (III, IV, VI) responsible for eye movement can be weak or palsied and cause strabismus. Some examples of paralytic strabismus include third nerve palsy and superior oblique palsy.
- Eye misalignment can cause amblyopia in children.
- the brain receives 2 different visual images.
- the brain may ignore the image from the misaligned eye to avoid double vision, resulting in poor vision development of that eye. Also, an eye that sees poorly tends to be misaligned.
- Vision Therapy includes the eye muscle training methods, it includes training and rehabilitation of the eye-brain connections (neuro-lplasticity) involved in vision.
- vision therapy is defined as an attempt to develop or improve visual skills and abilities; improve visual comfort, ease, and efficiency; and change visual processing or interpretation of visual information.
- An optometnc vision therapy program consists of supervised in-office and at home reinforcement exercises performed over weeks to months Clinical and research developments in Vision Therapy are allied with developments in neuroscience and research continues (www.trabismus.org; www.aapos.org).
- Glaucoma and Optic Nerve Atrophy are a complicated disease in which damage to the optic nerve leads to progressive, irreversible vision loss. Glaucoma is the second leading cause of blindness. The increased pressure, called intraocular pressure, can damage the optic nerve, which transmits images to the brain. If damage to the optic nerve from high eye pressure continues, glaucoma will cause permanent loss of vision. Without treatment, glaucoma can cause total permanent blindness within a few years.
- Glaucoma usually occurs when pressure in your eye increases. This can happen when eye fluid isn't circulating normally in the front part of the eye. Normally, this fluid, called aqueous humor, flows out of the eye through a mesh-like channel. If this channel becomes blocked, fluid builds up, causing glaucoma. Less common causes of glaucoma include a blunt or chemical injury to the eye, severe eye infection, blockage of blood vessels in the eye, inflammatory conditions of the eye, and occasionally eye surgery to correct another condition. Glaucoma usually occurs in both eyes, but it may involve each eye to a different extent.
- glaucoma There are two main types of glaucoma: (a) Open-angle glaucoma. Also called wide- angle glaucoma, this is the most common type of glaucoma. The structures of the eye appear normal, but fluid in the eye does not flow properly through the drain of the eye, called the trabecular meshwork. (b) Angle-closure glaucoma. Also called acute or chronic angle-closure or narrow-angle glaucoma, this type of glaucoma is less common but can cause a sudden buildup of pressure in the eye. Drainage may be poor because the angle between the iris and the cornea (where a drainage channel for the eye is located) is too narrow (sources: www.webmd.com, www. Glaucoma.org)
- ERPs Event-Related Potentials
- VEPs flash visual evoked potentials
- PD idiopathic Parkinson's disease
- AD Alzheimer dementia
- P3 and flash- VEP N2, P2 and delta (P2-P1) latency measures were significantly increased in the demented PD group compared with controls.
- the ERP P3 latency was also significantly delayed in the AD group compared with controls (Gerontology. 1993;39(4):228-40.; Parkinson's dementia and Alzheimer's dementia: an evoked potential comparison).
- ERP and VEPs were discussed as means to identify and quantify neurological dysfunction in AD patients. It is contemplated that plasticity of neurological connections may be promoted using customized auditory and visual stimulation, in the form of specific video and audio presentations and stimulus, serving as light and sound stimulations, as well as cognitive stimulation due to the engagement of the patient in the presented content .
- ADHD and ADHD Attention deficit hyperactivity disorder (ADHD) and attention deficit disorder (ADD) symptoms may begin in childhood and continue into adulthood. ADHD and ADD symptoms, such as hyperactivity, impulsiveness and inattentiveness, can cause problems at home, school, work, or in relationships. scientistss are not sure what causes ADHD, although many studies suggest that genes play a large role. Like many other illnesses, ADHD probably results from a combination of factors. In addition to genetics, researchers are looking at possible environmental factors, and are studying how brain injuries, nutrition, and the social environment might contribute to ADHD. (source: National Institute For Mental Health, www.nimh.nih.gov).
- STROKE Ischemic stroke produces cell death and disability, and a process of repair and partial recovery. Plasticity within cortical connections after stroke leads to partial recovery of function after the initial injury. Physiologically, cortical connections after stroke become hyperexcitable. (Plasticity of cortical projections after stroke. Neuroscientist. 2003 Feb;9(l):64-75. Stroke induces a process of axonal sprouting in neighboring or connected cortical neurons that is associated with repair and recovery. Maintaining tissue perfusion in the area surrounding the infarct could hasten or augment synaptic plasticity and functional recovery after stroke. (Local Hemodynamics Dictate Long-Term Dendritic Plasticity In Peri- Infarct Cortex., J Neurosci. 2010 Oct 20; 30(42)).
- a system for treating brain related medical conditions of a patient comprising: a head- mountable apparatus comprising at least one lens having a see-through field-of-view;at least one programmable component configured to display at least one artificial visual stimulus seen by said patient in said see-through field-of-view;a database containing at least one predetermined protocol for controlling said artificial visual stimulus;wherein said programmable component contains instructions for affecting the image presentation of said artificial visual stimulus in least one portion of at least one lens according to a predetermined regime.
- the medical conditions are selected from the group comprising of, but not limited to, amblyopia, strabismus, glaucoma, Parkinson's disease, ischemic stroke, Alzheimer, other brain diseases and conditions and any combination thereof.
- the system enhances blood flow and perfusion to the brain by means of the artificial visual stimulus protocol.
- the system is characterized by the following: at least one of lens is opaque; at least one near eye light emitting component of a list comprising: LED, bulb light or fluorescent, wherein said light emitting device is controlled by said programmable component to provide for a visual stimuli; a user interface device allows the user to alter the protocol affecting the stimuli levels; and the system can be controlled remotely.
- the programmable component is further configured to provide at least one audible stimulus, to provide said artificial visual stimulus and/or audible stimulus wirelessly.
- the artificial visual stimulus is dynamically adaptive to the ambient lighting conditions.
- the system uses the results of a computerized refractive eye exam to automatically affect the protocol of visual stimuli provided by the system.
- the level of at least one parameter of the artificial visual stimulus out of a list comprising; brightness, contrast, saturation, blur or sharpness, is altered dynamically with respect to the characteristics of at least one visible element in the presented image itself.
- no stimuli is provided to allow for the user's organs to rest.
- at least one display area is darkened to allow for the user's organs to rest.
- the actual viewing area on at least one display is partial, thereby allowing for shifting of the viewing area in a direction out of a list comprising: upwards, downwards, sideways or any combination thereof, with respect to the natural viewing plain.
- a system for training the eye muscles comprising: a controller connectable to a streaming video content; a memory component for storing a regimen; at least one near eye display having a display area; wherein at least one moving object superimposed on the video content in real time, is displayed on at least one near eye display, in accordance to a predetermined regimen.
- the system provides an audio stimuli out of a list comprising: spoken description of the object, a sound commonly associated with the moving object, a distinct sound; in conjunction with the superimposed object.
- the regimen alters a presented image's properties to at least one near-eye display our of a list comprising: brightness, contrast, saturation, monochromatic or any combination thereof. Also, the regimen alters a size of the presented image's at least one near-eye display and the regimen alters a position of the presented image's at least one near-eye display.
- the system enhances blood flow and perfusion to the brain by means of the artificial visual stimulus protocol.
- the system is configured to substantially isolate user's eyes from external visual disturbances.
- the system further comprising a data logger.
- An apparatus for treating brain related medical conditions of a patient comprising: a head-mountable apparatus comprising at least one lens having a see-through field-of-view;at least one programmable component configured to display at least one artificial visual stimulus seen by said patient in said see-through field-of-view;wherein said system further comprises a database containing at least one predetermined protocol; and further wherein said artificial visual stimulus is derived from said at least one predetermined protocol.
- the apparatus can be powered by a battery cell,wirelessly powered, powered from an outlet within a device having an outlet from the group comprising: HDMI, USB, Mini-USB and Micro USB, or any combination thereof.
- the apparatus comprises a controller unit and a wireless receiving unit, and can be controlled remotely. It also comprises a data logger.
- a head mounting apparatus for positioning a video display component in from of a person's eye, for treating a brain related medical condition comprising: an ergonomic fixing head brace for a near eye display component; and a compartment for fixing an electronic image display component;wherein said compartment is adapted for replacing the electronic image display component, when the electronic display is intended to be reused by more than one person.
- a brain and eye stimulation software application for use with a mobile computerized device, for altering the video image as presented on at least one near-eye video display comprising at least: (a) one digital video filter, for alternating at least one characteristic; (b) triggering changes of the display properties; and(c) an on screen display of a superimposed object; wherein the stimulation is achieved by altering the presentation of an image on said near eye display in accordance to a protocol operated by said software application.
- the software application alternates the viewed image properties on at least one display of the lens having a see-through field-of-view, and is obtained by way of altering at least one parameter of the video data sent to least one display of the binocular device.
- the software application the shifts at least one image presented on at least one display, such shift may be up-down-left-right, whereas the shift is achieved by means of a command to a controller (or driver) connected to said displays or screens.
- the software application comprises two display areas; wherein a dichoptic view is achieved by a video data stream that is SIDE by SIDE encoded, Frame Sequential encoded or Field Sequential encoded.
- a binocular video eyewear system for treating a medical condition comprising;at least two display components;at least two display driver components;a controller; anda memory component connected to said controller;wherein according to a predetermined regimen, the controller commends a display driver to alter of at least one image parameter of at least one display, out of a list comprising: brightness, contrast, saturation, monochromatic or any combination thereof.
- a method for training the brain and visual system using involuntary learning by a passive user comprising: obtaining a set of near-eye video display, having at least one display area having a see-through field-of-view; repetitive presenting of a superimposed image on said at least one display area; and providing a non-visual stimuli in conjunction with said superimposed image; wherein the user associates the image with the sound, thus the user's brain experiences perceptual learning without voluntary engagement of the user.
- FIG. 1 schematically presents the system for the visual stimulation of the brain.
- FIG. 2 schematically presents the system for the visual stimulation of the brain,said system comprises a software application (APP) and by way of illustration, a Tablet PC.
- APP software application
- Tablet PC Tablet PC
- FIG. 3 schematically presents thesystem comprising a visual stimuli generator and a visual stimuli superimposed on the general viewing area of a pair of spectacles.
- FIG. 4 illustrate an embodiment of a predetermined protocol.
- the present invention uses a combination of stimuli means and relies on a combination of physiological phenomena and provides a novel treatment approach along with a system and a method.
- the invention uses novel visual and audible stimuli protocols, which may be materialized by controlling specific characteristics of visual and audio data as presented to the human senses.
- the invention uses brain stimulation, based on controlling the levels and characteristics of the light energy and acoustic energy.
- the present invention may also utilize mechanical-physical stimulation such as direct or indirect mechanical vibration stimuli.
- the present invention facilitates activation of brain areas using audio-visual stimuli, while the user is principally PASSIVE, e.g. is not required to take a voluntary action to affect the treatment. Furthermore, the passive nature of being exposed to an audio-visual content, allows for the user to be focused on the presentation of the content, thereby being FOCUSED on the stimuli. This focus, contributes to the effect of the stimuli in various areas of the brain, including ones involved in interpretation of data.
- the present invention facilitates for a novel treatment that stimulates the activity of residual or deficient neurological connections in the visual system and other brain areas, while at the same time it encourages formation of new neurological connections.
- results from a prospective clinical study aimed to evaluate the efficacy of the invention as a possible treatment for Amblyopia indicated significant improvement of 2 LogMar lines in visual acuity of the subjects within 4 weeks of treatment.
- the reactivation of the Amblyopic eye visual pathway facilitates overcoming the suppression by the fellow eye in the various sections of the visual system (LGN and VI), and provides proof the stimuli indeed promoted brain plasticity.
- the present invention affects the user's blood flow and perfusion level in the brain, which are elevated as a result of the increase in Nitric Oxide produced. This effect reduces user fatigue while using the disclosed invention, contributes to the overall metabolism in the visual system, and thus contributes to re-generation of neurological connections.
- Watching video content using the present invention exposes the user to light and acoustic energies. It evokes neural activity in the retina at several levels, an activity later translated to signals represented in the LGN and the cortex.
- the Present invention displays to the Amblyopic eye a visual stimulus (dynamic video image) characterized by (i) increased contrast, combined with; (ii) increase luminance i.e. brightness, thus affecting increased electric signaling.
- the increased signal "overcomes" the inherent noise of the Amblyopic eye in parts of the visual system, a noise resulting from the loosening of the neurological connections, in the neurological driven by the Amblyopic eye.
- the present invention utilizes stimuli affecting a passive visual learning. Overlay images, superimposed on to the video content presented, and traveling through the frame, stimulate the visual cortex and are believed to contribute to driving plastic changes, as the brain "learns" the travel patters as the eyes follow the objects travel. As the travel path is repetitive, and is associated with a pre-alerting sound effect, it is assumed to affect learning.
- the present invention may include auditory stimuli.
- the use of auditory stimuli, with increased intensity to any of the eyes for example, serves three purposes: (a) The auditory stimulus secures the patient's attention to the visual stimuli, which is enhanced by the auditory input (music, sound effects, meaningful talking of characters viewed on the displays). The patient is therefore drawn into the visual experience, and thus is highly attentive to the visual stimuli. (b) The auditory stimulus compensates for the poor visual capacity, especially at early stages of the treatments period (until enough improvement in acuity is achieved). It is important to note that the auditory input is instrumental in maintaining the coherence of the watching experience, especially in patients with poor visual acuity at an eye.
- the auditory stimuli evokes a corresponding neurological response in the visual cortex.
- stimuli regimens that includes rest and rebalance intervals.
- Temporary darkening of both displays of the present invention and indented darkening of any of the displays are intended to improve the effect evoked by the stimuli provided immediately after the period of darkening.
- the present invention provides for a novel concept of a PASSIVE treatment, whereas in the preferred embodiments of the invention, the user is merely required to watch and listen to an audio-visual content, and said watching and listening provides for the stimuli to be received, processed and affect the physiology of the user, whiteout requirement for any conscious response or involvement. Therefore, the benefit of the present invention may apply also when used as the user is asleep.
- the present invention is claimed to be useful for the treatment of various medical conditions, including amblyopia, strabismus andglaucoma. Strabismus is almost always caused by a limitation of ocular rotations that is due to a restriction of extraocular eye movement (ocular restriction) or due to extraocular muscle paresis.
- the present invention can be used to "train" the extraocular muscles using tracking of moving objects superimposed on any video content, thus may be an adjunct or even an alternative to surgery, we offer a very compelling, safe, cost effective solution.
- Treating Glaucoma and Optic Nerve Atrophy - the present invention may be either adjunct and in some cases alternate to available treatments to contribute to eye fluids draining, contribute to reversing optic nerve atrophy, to avoid vision loss.
- the present invention is claimed to use the visual and auditory pathways to affect the non-properly functioning neurological connections and or restore and ⁇ or stimulate formation of new neurological connections affected by this condition in conjunction or as a surrogate to medication when treating Parkinson's disease.
- the present invention is claimed to use the visual and auditory pathways to affect the non-properly functioning neurological connections and or restore and ⁇ or stimulate formation of new neurological connections affected by this condition in conjunction or as a surrogate to medication when treating an ischemic stroke.
- the present invention is claimed to provide for a novel system and method for affecting the eye muscles to be retract and relax, utilizing regimens comprising; moving objects viewed on at least one screen or display area of a binocular display mean, wherein an eye designated for training follows the viewed moving objects superimposed on any displayed video content in contemporary on what is being watched through the screen or display.
- treatment protocols comprising a regimen of alternating at least one image property, in at least one display or screen connected to source device: hue, brightness, saturations, contracts, color ⁇ black and white, resolution, zoom-in, zoom-out, shift left-right-up-down.
- treatment protocols comprising a regimen of alternating at least one image property, in at least one display or screen connected to source device: hue, brightness, saturations, contracts, color ⁇ black and white, resolution, zoom-in, zoom-out, shift left-right-up-down.
- Such alternation of the display properties may be triggered by either command signal delivered to the display from a controller (for example an computer or a Smartphone) or mechanical device (for example a switch).
- a controller for example an computer or a Smartphone
- mechanical device for example a switch
- Such alternation of the display properties may be pre-programmed to reflect a predetermined protocol.
- Such protocol may be embedded in an IC controlling the display or screen operation, or an IC external to said display or screen device.
- visual stimuli in the form of a flicker or a flash, presented on at least one display or screen of a binocular device, in a predetermined or arbitrary sequence, or any combination thereof.
- Said visual stimuli may be, but not necessarily, stopped, delayed or renewed by a command provided by a triggering device controlled by the viewer, such as a human interface device.
- a system as described comprising a user operated input device, allowing the user to seize, alter and ⁇ or restart a visual stimuli presented to him.
- a dichoptic view binocular video eyewear system said eyewear comprising a, or connected to, an IC and a protocol for displaying visible objects (superimposed or standalone) on at least one display or screen of said binocular video eyewear system, wherein the objects re superimposed on the then displayed image, or on its own (no specific background or superimposing).
- a distinct sound is played to at least one ear, such a sound may be, but not necessarily, a voice calling out the name or description of said object, a sound otherwise associated with it (for example, an image of a dog, accompanied by a dog barking, or the sound of the word DOG).
- a protocol for stimuli of the brain and ⁇ or eye comprising at least one appearance of a superimposed visible object, and at least one of the following characteristics: an appearance point, a disappearance point, a movement pattern, movement speed, movement direction.
- Said protocol preferably but not necessarily be accompanied with a stimuli of an ear, an audible sound, said sound having a duration, intensity, level and tune.
- a dichoptic stimuli protocol combining any of said stimuli of an eye with any said stimuli of an ear, wherein each eye and each ear may be subject to a different visual or auditable stimuli then the fellow eye or ear.
- the visual stimuli is a super-imposed overlay image, presented to at lease of the users eye, and wherein the super-imposed image parameters may be dichoptically presented to each eye, by way of differential movement pattern, size, location or appearance.
- the protocol disclosed may be incorporating several modules.
- a 30 min protocol may comprise 3 sets of 10 modules each (A,B,C).
- Each module may comprise, by way of illustration, 4 sub modules (A1,A2,A3,A4 and B1,B2 etc .).
- Each sub- module may be characterized by specific display parameters, and audio parameters, that may vary between a one eye and the fellow eye, and respective ears.
- display parameters and audio parameters, that may vary between a one eye and the fellow eye, and respective ears.
- audio parameters that may vary between a one eye and the fellow eye, and respective ears.
- the brightness and contrast are 25% above normal, and a superimposed image of a car appears 8 times on the one display, while the sound level to respective ear is elevated by 30%.
- the other display brightness and contrast are decreased by 25%, and the sound level in respective ear is decreased by 30%.
- weak eye module A2 (duration 30 seconds) the brightness and color saturation are 15% above normal, and a flickers (white, blue, red, green, yellow, purple, turquoise or any combination thereof) appears 5 times on one display, accompanied by a lightning sound heard only in respective ear.
- the second display brightness and color saturation are decreased by 20%.
- the protocol comprises alteration of properties only of the image presented to one eye.
- a predetermined ratio is maintained between the properties of the image as presented on each display.
- the disclosed invention provides for a dichoptic view binocular video presenting eyewear; wherein a dichoptic view is achieved by a video stream of (a) SIDE by SIDE video data or; (b) Field Sequential video data, (c) Frame Sequential video data, (d) video data superimposed on an otherwise transparent lenses, i.e. augmented reality goggles or (e) altering the presentation of the video data by way of altering the properties of a presentation device (display, projector etc.) affecting the properties of an image as presented.
- a presentation device display, projector etc.
- Each of the aforesaid may be utilized to affect the dichoptic presentation thus the stimulation of the brain, eyes, ears and any combination thereof.
- the disclosed system comprising at least one near-eye display, wherein the display device is configured to substantially isolate user's eyes from external visual disturbances.
- a system as described wherein the display device is mounted on a an everyday like spectacles or is a set of augmented reality spectacles, wherein a visible stimuli is provided to the eye by way of presenting an image, an abstract form or text based stimuli as an add-on to the otherwise visible viewing area.
- the display device could be any of the following: Google Glass, the Atheer One, GlassUp, Epson Moverio BT-200, Vuzix Ml 00 or otherwise augmented reality devices using micro-projector or pi co-projector components.
- controller unit additionally comprises a data storage device adapted to be operatively connected to the controller unit configured to store the predetermined regime.
- controller unit comprises a graphic processing unit configured to alter at least one image parameter according to the predetermined regime.
- At least one display parameter is selected from the group containing brightness, contrast, saturation, sharpness, resolution, or other conventional parameters and combinations thereof.
- controller unit is additionally configured to insert at least one overlay of at least one object on at least one displaying area.
- controller unit is additionally configured to trigger audio data configured to be coherently connected to inserting of at least one generated overlay of at least one object according to the predetermined regime.
- the controller unit is additionally configured to introduce at least one flicker event on at least one displaying area
- the flicker may be in the form of a video frames sequence, or an external light source such as an Light Emitting Diode (LED).
- LED Light Emitting Diode
- the disclosed system connectable to a visual content source selected from the group consisting of a video game console, cable modem, a television, a computer, a digital camera, a camcorder, a DVD, a mobile phone, a portable media player, an offline video content storage device, and a network online streaming video content.
- a visual content source selected from the group consisting of a video game console, cable modem, a television, a computer, a digital camera, a camcorder, a DVD, a mobile phone, a portable media player, an offline video content storage device, and a network online streaming video content.
- a system as described above powered from a DVI, HDMI, USB, Mini -USB or Micro USB outlets of a visual content source selected from the group consisting of a video game console, cable modem, a television, a computer, a digital camera, a camcorder, a DVD, a mobile phone, a portable media player, an offline video content storage device, and a network online streaming video content.
- a visual content source selected from the group consisting of a video game console, cable modem, a television, a computer, a digital camera, a camcorder, a DVD, a mobile phone, a portable media player, an offline video content storage device, and a network online streaming video content.
- FIG. l schematically presenting the system for the visual stimulation of the brain.
- the head set receives a script data comprising a protocol/regime which transmits to the see-through field-of-view displays and to the earpieces.
- the head set in this example is powered from an USB outlet.
- the disclosed system receiving electrical power from a solar energy device.
- FIG.2 schematically presents the system for the visual stimulation of the brain,said system comprises a software application (APP) and by way of illustration, a Tablet PC.
- the head set receives a script data comprising a protocol/regime from the Tablet PC, which transmits to the see-through field-of-view displays and to the earpieces.
- the Tablet PC comprises all the necessary software information to run the protocols.
- the disclosed system connectable to a either a PC, Tablet PC, mobile phone, PDA or a screen-less computerized device; wherein said computerized device communicates (by wire or wirelessly) with said system as described above, to provide for a user interface, data storage, video content selection, video data conveying, logging and storing logs of the use of the system, transmitting the logs of the use of the system, or any combination thereof.
- FIG.3 schematically presents the system comprising a visual stimuli generator and a visual stimuli superimposed on the general viewing area of a pair of spectacles.
- the system described above, whereas the dichoptic presentation is executed via: (a) at least one display component, (b) at least one display driver component, and (c) a controller component, commanding the driver component to alter at least one display parameter in realtime, by way of example change the brightness or the contrast of the image presented on said display.
- the controller may command more than one driver, and whereas a driver is connected to a specific display component, said display component will alter the presentation of the image presented by it.
- a sequence of such commands preferably but not necessarily different to each driver and thus display, may provide for a dichoptic presentation of the same image, while presented on two display components, by way of example in a set of video goggles.
- the regimen upon which the controller commends the drivers may affect a presented image display parameter from the group containing brightness, contrast, saturation, sharpness, resolution, or other conventional parameters and combinations thereof as well as superimposed visual data.
- a visual stimuli protocol is provided using the above system, wherein the intensity and regimen of the stimuli, is dynamically adopted to the properties of the then displayed image (e.g., content).
- a visual stimuli protocol is provided using the above system, wherein the protocol comprises segments whereas at least one the display is a darkened for a predetermined period of time.
- a system as described above comprising at least one light emitting diode (LED) positioned in proximity to the display area, for providing a visual stimuli to the eye.
- the led may provide for flicker or flash stimuli independently or in conjunction to the audio-visual stimuli via the content.
- FIG.4 illustrate an embodiment of a predetermined protocol.
- Graph coordinates the dynamic changes in the parameters of the displayed image.
- the dotted line refers to the contrast.
- Continuous line refers to the level of brightness.
- the exposure to the weak eye is mostly done with high contrast and brightness relative to the baseline ("neutral" presentation).
- the exposure to the strong eye is mostly done with low level of brightness and contrast lower relative to the baseline.
- the higher peaks, in the continuous line reflect a state of about over a predeterminedlevel of brightness, meaning bright/white screen.
- the lower peaks, in the continuous line reflect a state of about below a predetermined level brightness, meaning dark/black screen.
- a method for treating an eye or brain related condition comprising alteration of a visual and audio stimuli provided to a subject, by way of altering the presentation of a visible and audible content presented to a subject, in which at least one of the following occurs at least one time over a treatment session: the Brightness of the presented image to one eye is elevated comparing to a native image; the Contrast of the presented image to one eye is elevated comparing to a native image; the Sharpness of the presented image to one eye is elevated comparing to a native image; the Chroma of the presented image to one eye is elevated comparing to a native image; the Volume level of a sound associated with said presented image, is elevated comparing to a native volume level; the Brightness of the presented image to one eye is decreased comparing to a native image; the Contrast of the presented image to one eye is decreased comparing to a native image; the Sharpness of the presented image to one eye is decreased comparing to a native image; the Chroma of the presented
- [I l l] A system as described above, comprising a computerized refractive eye exam wherein the results of the exam affect the regimen of brain visual stimuli used to treat a brain related medical condition.
- the level of at least one parameter of the image's presentation (brightness, contrast, saturation, blur, sharpness) is altered in real time in conjunction to the image's content lighting level (for example a bright outdoor image, or a dark night image).
- the compartment is designed to allow for easily replacing the electronic image display, for disposing the fixing head brace, when the electronic display is to be used by more than one person.
- the disposable fixing allows for different users to use the same image display without compromising sanitary of the display. This is useful also to reduce costs, as the display is typically much more expensive then the head mounting brace.
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Theoretical Computer Science (AREA)
- Computer Hardware Design (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Rehabilitation Therapy (AREA)
- Physical Education & Sports Medicine (AREA)
- Human Computer Interaction (AREA)
- General Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rehabilitation Tools (AREA)
Abstract
L'invention concerne un système pour traiter des états médicaux liés au cerveau d'un patient, tels qu'une amblyopie, un strabisme, un glaucome, la maladie de Parkinson, un accident ischémique cérébral, Alzheimer, d'autres maladies et états cérébraux, comprenant : un appareil pouvant être monté sur la tête comprenant au moins une lentille ayant un champ de vision traversant ; au moins un élément programmable configuré pour afficher au moins un stimulus visuel artificiel vu par ledit patient dans ledit champ de vision traversant ; une base de données contenant au moins un protocole prédéterminé pour commander ledit stimulus visuel artificiel, ledit élément programmable contenant des instructions pour affecter la présentation d'image dudit stimulus visuel artificiel dans au moins une partie d'au moins une lentille en fonction d'un régime prédéterminé. Le système améliore le débit sanguin et la perfusion du cerveau au moyen du protocole de stimulus visuel artificiel.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361902173P | 2013-11-09 | 2013-11-09 | |
US61/902,173 | 2013-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015068168A1 true WO2015068168A1 (fr) | 2015-05-14 |
Family
ID=53040988
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2014/050974 WO2015068168A1 (fr) | 2013-11-09 | 2014-11-09 | Système et procédé pour traiter des troubles de l'œil et du cerveau |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015068168A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105640749A (zh) * | 2016-01-05 | 2016-06-08 | 马贤举 | 一种视力保护眼镜及矫正视力的方法 |
US20190076670A1 (en) * | 2017-09-11 | 2019-03-14 | Alzheimer's Light Llc | Flashing Light Therapy with Image Presentation and Interaction for Treatment of Alzheimer's Disease and Dementia |
CN110123594A (zh) * | 2019-05-04 | 2019-08-16 | 吴登智 | 一种用于弱视训练的vr与智能终端同步显示系统 |
CN110300567A (zh) * | 2016-12-15 | 2019-10-01 | 埃登卢克斯公司 | 用于改善融合功能的视力训练装置 |
US20200030150A1 (en) * | 2017-03-20 | 2020-01-30 | Veysel OZKAPICI | Glaucoma treatment eyeglass with visual stimulation |
US11281893B2 (en) | 2016-06-21 | 2022-03-22 | Stefan Zechner | Method and device for modifying the affective visual information in the field of vision of an user |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264877A (en) * | 1989-07-27 | 1993-11-23 | Hussey Eric S | Eyeglasses for use in the treatment/diagnosis of certain malfunctions of the eye |
US20060087618A1 (en) * | 2002-05-04 | 2006-04-27 | Paula Smart | Ocular display apparatus for assessment and measurement of and for treatment of ocular disorders, and methods therefor |
US20090109398A1 (en) * | 2005-10-14 | 2009-04-30 | Nir Ellenbogen | Apparatus for Improving Visual Perception |
US20090156886A1 (en) * | 2007-12-12 | 2009-06-18 | Synapse Research Company | Method and apparatus for providing automatic eye focused therapy |
US20100073469A1 (en) * | 2006-12-04 | 2010-03-25 | Sina Fateh | Methods and systems for amblyopia therapy using modified digital content |
US20100283969A1 (en) * | 2007-10-23 | 2010-11-11 | Mcgill University | Binocular vision assessment and/or therapy |
US20120179076A1 (en) * | 2010-09-16 | 2012-07-12 | Daphne Bavelier | Method and system for treating amblyopia |
US20130100402A1 (en) * | 2011-10-12 | 2013-04-25 | Salus University | Systems and methods for reducing sensory eye dominance |
US20130293531A1 (en) * | 2012-05-01 | 2013-11-07 | Microsoft Corporation | User perception of visual effects |
-
2014
- 2014-11-09 WO PCT/IL2014/050974 patent/WO2015068168A1/fr active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5264877A (en) * | 1989-07-27 | 1993-11-23 | Hussey Eric S | Eyeglasses for use in the treatment/diagnosis of certain malfunctions of the eye |
US20060087618A1 (en) * | 2002-05-04 | 2006-04-27 | Paula Smart | Ocular display apparatus for assessment and measurement of and for treatment of ocular disorders, and methods therefor |
US20090109398A1 (en) * | 2005-10-14 | 2009-04-30 | Nir Ellenbogen | Apparatus for Improving Visual Perception |
US20100073469A1 (en) * | 2006-12-04 | 2010-03-25 | Sina Fateh | Methods and systems for amblyopia therapy using modified digital content |
US20100283969A1 (en) * | 2007-10-23 | 2010-11-11 | Mcgill University | Binocular vision assessment and/or therapy |
US20090156886A1 (en) * | 2007-12-12 | 2009-06-18 | Synapse Research Company | Method and apparatus for providing automatic eye focused therapy |
US20120179076A1 (en) * | 2010-09-16 | 2012-07-12 | Daphne Bavelier | Method and system for treating amblyopia |
US20130100402A1 (en) * | 2011-10-12 | 2013-04-25 | Salus University | Systems and methods for reducing sensory eye dominance |
US20130293531A1 (en) * | 2012-05-01 | 2013-11-07 | Microsoft Corporation | User perception of visual effects |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105640749A (zh) * | 2016-01-05 | 2016-06-08 | 马贤举 | 一种视力保护眼镜及矫正视力的方法 |
US11281893B2 (en) | 2016-06-21 | 2022-03-22 | Stefan Zechner | Method and device for modifying the affective visual information in the field of vision of an user |
CN110300567A (zh) * | 2016-12-15 | 2019-10-01 | 埃登卢克斯公司 | 用于改善融合功能的视力训练装置 |
EP3556339A4 (fr) * | 2016-12-15 | 2020-08-19 | Edenlux Corporation | Dispositif d'entraînement visuel pour l'amélioration de la vergence fusionnelle |
US11110027B2 (en) | 2016-12-15 | 2021-09-07 | Edenlux Corporation | Vision training device for improving fusional vergence |
CN110300567B (zh) * | 2016-12-15 | 2022-01-21 | 埃登卢克斯公司 | 用于改善融合功能的视力训练装置 |
US20200030150A1 (en) * | 2017-03-20 | 2020-01-30 | Veysel OZKAPICI | Glaucoma treatment eyeglass with visual stimulation |
US11903880B2 (en) * | 2017-03-20 | 2024-02-20 | Glaucot Teknoloji Anonim Sirketi | Glaucoma treatment eyeglass with visual stimulation |
US20190076670A1 (en) * | 2017-09-11 | 2019-03-14 | Alzheimer's Light Llc | Flashing Light Therapy with Image Presentation and Interaction for Treatment of Alzheimer's Disease and Dementia |
CN110123594A (zh) * | 2019-05-04 | 2019-08-16 | 吴登智 | 一种用于弱视训练的vr与智能终端同步显示系统 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10962789B1 (en) | Digital eyewear system and method for the treatment and prevention of migraines and photophobia | |
US10716469B2 (en) | Ocular-performance-based head impact measurement applied to rotationally-centered impact mitigation systems and methods | |
JP7333432B2 (ja) | ユーザ健康分析のための拡張現実システムおよび方法 | |
EP3472828B1 (fr) | Système d'affichage en réalité augmentée pour l'évaluation et la modification de troubles neurologiques, notamment des troubles du traitement de l'information visuelle et des troubles de la perception visuelle | |
WO2015068168A1 (fr) | Système et procédé pour traiter des troubles de l'œil et du cerveau | |
KR102634148B1 (ko) | 건강 질환 진단과 치료를 위한 방법 및 시스템 | |
US11490809B2 (en) | Ocular parameter-based head impact measurement using a face shield | |
US20190046758A1 (en) | Methods for Independent Entrainment of Visual Field Zones | |
US10602927B2 (en) | Ocular-performance-based head impact measurement using a faceguard | |
CN105748268B (zh) | 用于治疗眼睛疾病的3d图像系统 | |
Yadav et al. | Effect of oculomotor vision rehabilitation on the visual-evoked potential and visual attention in mild traumatic brain injury | |
Ciuffreda et al. | Effect of binasal occlusion (BNO) on the visual-evoked potential (VEP) in mild traumatic brain injury (mTBI) | |
TW201545713A (zh) | 視力保護方法及其系統 | |
CN103876886A (zh) | 一种弱视治疗系统 | |
US20140024883A1 (en) | Device and method for stimulating eye movement | |
CN103784298A (zh) | 一种头戴式个性化人眼像差矫正视觉训练仪 | |
US20230296895A1 (en) | Methods, apparatus, and articles to enhance brain function via presentation of visual effects in far and/or ultra-far peripheral field | |
US20150025301A1 (en) | Device and method of stimulating eye movement | |
Schulz | Facilitators and barriers to technology uptake: Individual end-user perspectives | |
CN105748269B (zh) | 治疗眼睛疾病的3d图像系统 | |
US20220152339A1 (en) | System and method for enhancing or rehabilitating the cognitive skills of a subject | |
Janssen | Virtual visual cues: vice or virtue? | |
US12099654B1 (en) | Adaptation of electronic content | |
Sipatchin | Keep your eyes above the ball: investigation of virtual reality (VR) assistive gaming for age-related macular degeneration (AMD) visual training | |
US20200330789A1 (en) | Ganzfeld Contact Lenses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14860436 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14860436 Country of ref document: EP Kind code of ref document: A1 |